MBX Biosciences (MBX) Accounts Payables (2023 - 2026)

MBX Biosciences has disclosed Accounts Payables across 4 years of filings, most recently posting $7.0 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $7.0 million, up 64.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (up 64.29% YoY), and the FY2025 annual result was $3.0 million, down 44.2% from the prior year.
• Accounts Payables came in at $7.0 million for Q1 2026 at MBX Biosciences, up from $3.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.0 million in Q1 2026 to a low of $1.4 million in Q4 2023.
• The 4-year median for Accounts Payables is $4.6 million (2024), against an average of $4.4 million.
• Across the five-year window, Accounts Payables surged 283.54% in 2024 and slumped 44.2% in 2025, its largest moves.
• MBX Biosciences' Accounts Payables stood at $1.4 million in 2023, then soared by 283.54% to $5.3 million in 2024, then plunged by 44.2% to $3.0 million in 2025, then soared by 134.26% to $7.0 million in 2026.
• The last three Accounts Payables figures came in at $7.0 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.